392 related articles for article (PubMed ID: 17881660)
1. Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase.
Kousba A; Soll R; Yee S; Martin M
Drug Metab Dispos; 2007 Dec; 35(12):2242-51. PubMed ID: 17881660
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
[TBL] [Abstract][Full Text] [Related]
3. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.
Rawden HC; Kokwaro GO; Ward SA; Edwards G
Br J Clin Pharmacol; 2000 Apr; 49(4):313-22. PubMed ID: 10759686
[TBL] [Abstract][Full Text] [Related]
4. A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes.
Grothusen A; Hardt J; Bräutigam L; Lang D; Böcker R
Arch Toxicol; 1996; 71(1-2):64-71. PubMed ID: 9010587
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
Rodrigues AD; Mulford DJ; Lee RD; Surber BW; Kukulka MJ; Ferrero JL; Thomas SB; Shet MS; Estabrook RW
Drug Metab Dispos; 1995 Jul; 23(7):765-75. PubMed ID: 7587966
[TBL] [Abstract][Full Text] [Related]
6. Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase.
Arlt VM; Stiborova M; Hewer A; Schmeiser HH; Phillips DH
Cancer Res; 2003 Jun; 63(11):2752-61. PubMed ID: 12782579
[TBL] [Abstract][Full Text] [Related]
7. Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor.
Kim YW; Kim YK; Kim DK; Sheen YY
Xenobiotica; 2008 May; 38(5):451-64. PubMed ID: 18421620
[TBL] [Abstract][Full Text] [Related]
8. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.
Parte P; Kupfer D
Drug Metab Dispos; 2005 Oct; 33(10):1446-52. PubMed ID: 15987777
[TBL] [Abstract][Full Text] [Related]
9. In vitro metabolism of clindamycin in human liver and intestinal microsomes.
Wynalda MA; Hutzler JM; Koets MD; Podoll T; Wienkers LC
Drug Metab Dispos; 2003 Jul; 31(7):878-87. PubMed ID: 12814964
[TBL] [Abstract][Full Text] [Related]
10. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus).
Uehara S; Uno Y; Inoue T; Murayama N; Shimizu M; Sasaki E; Yamazaki H
Drug Metab Dispos; 2015 May; 43(5):735-42. PubMed ID: 25735838
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.
Lee CA; Kadwell SH; Kost TA; Serabjit-Singh CJ
Arch Biochem Biophys; 1995 May; 319(1):157-67. PubMed ID: 7771780
[TBL] [Abstract][Full Text] [Related]
12. Roles of FMO and CYP450 in the metabolism in human liver microsomes of S-methyl-N,N-diethyldithiocarbamate, a disulfiram metabolite.
Pike MG; Martin YN; Mays DC; Benson LM; Naylor S; Lipsky JJ
Alcohol Clin Exp Res; 1999 Jul; 23(7):1173-9. PubMed ID: 10443982
[TBL] [Abstract][Full Text] [Related]
13. S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes.
Ohmi N; Yoshida H; Endo H; Hasegawa M; Akimoto M; Higuchi S
Xenobiotica; 2003 Dec; 33(12):1221-31. PubMed ID: 14742144
[TBL] [Abstract][Full Text] [Related]
14. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
Zhang Y; Guo X; Lin ET; Benet LZ
Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
[TBL] [Abstract][Full Text] [Related]
16. The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s.
Potega A; Dabrowska E; Niemira M; Kot-Wasik A; Ronseaux S; Henderson CJ; Wolf CR; Mazerska Z
Drug Metab Dispos; 2011 Aug; 39(8):1423-32. PubMed ID: 21555506
[TBL] [Abstract][Full Text] [Related]
17. A novel class of cytochrome P450 reductase redox cyclers: cationic manganoporphyrins.
Day BJ; Kariya C
Toxicol Sci; 2005 May; 85(1):713-9. PubMed ID: 15703263
[TBL] [Abstract][Full Text] [Related]
18. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
19. Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of L-775,606, a potent 5-HT(1D) receptor agonist.
Prueksaritanont T; Lu P; Gorham L; Sternfeld F; Vyas KP
Xenobiotica; 2000 Jan; 30(1):47-59. PubMed ID: 10659950
[TBL] [Abstract][Full Text] [Related]
20. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?
Wagmann L; Meyer MR; Maurer HH
Toxicol Lett; 2016 Sep; 258():55-70. PubMed ID: 27320963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
